# Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

> **NCT00322348** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 98 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Goserelin acetate
- **DRUG:** Goserelin acetate

## Key facts

- **NCT ID:** NCT00322348
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2009-11
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322348, "Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00322348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*